How much funding has COUR Pharma raised?

COUR Pharma has raised $155.0M in total funding, most recently a Series B round.

Where is COUR Pharma headquartered?

COUR Pharma is headquartered in Evanston, United States.

COUR Pharma

Q: Who are COUR Pharma's investors?

COUR Pharma's investors include Lumira Ventures, Roche Venture Fund, Alpha Wave Ventures.

Evanston, United States · $155.0M raised

Headquarters: Evanston
Total Funding: $155.0M

Last Round: $50.0M Series BJun 2026
Rounds: 2

About

COUR Pharmaceuticals is an Evanston, Illinois clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune disease. Its proprietary COUR nanoparticles (CNPs) encapsulate disease-specific antigens and are engineered to mimic the anti-inflammatory signature of apoptotic cells, reprogramming upstream immune pathways to induce tolerance to those antigens rather than broadly suppressing immunity. The lead program, CNP-103, encapsulates four recombinant proteins believed to cover more than 95% of known type 1 diabetes antigens and is in an active Phase 2 randomised, double-blind, placebo-controlled trial (NCT06783309) in newly diagnosed patients aged 12-35. Additional candidates CNP-104 (primary biliary cholangitis) and CNP-106 (myasthenia gravis) are being partnered. The platform traces back to Stephen Miller's immune tolerance research at Northwestern University; CEO is Dannielle Appelhans.

Summary

COUR Pharma is a company based in Evanston, United States. It has raised $155.0M in total across 2 rounds, most recently a $50.0M Series B round in Jun 2026. Investors include Lumira Ventures, Roche Venture Fund and Alpha Wave Ventures.